NCT04489810

Brief Summary

This study evaluates the impact of two dietary supplements (Elevase® and DE111®) and of oatmeal properties on the digestion of gluten and starch and on the glycemic response.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 22, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 28, 2020

Completed
3 months until next milestone

Study Start

First participant enrolled

October 19, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 8, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 8, 2021

Completed
Last Updated

April 10, 2025

Status Verified

May 1, 2024

Enrollment Period

6 months

First QC Date

July 22, 2020

Last Update Submit

April 8, 2025

Conditions

Keywords

GlutenStarchDigestive enzymesProbiotics

Outcome Measures

Primary Outcomes (1)

  • Undigested wheat protein

    Difference between the mean concentration of undigested wheat protein in ileal effluent samples.

    9-hour period after the test meal

Secondary Outcomes (4)

  • Vegetative DE111 cells

    9-hour period after the test meal

  • Glycemic response

    At baseline, and at different time-points during 9 hours after after consuming the test meal.

  • Undigested starch

    At baseline and once every hour in the 9-hour period after consumption of the test meal.

  • Undigested food particles

    9-hour period after the test meal

Study Arms (4)

Meal A + Placebo

PLACEBO COMPARATOR

350 mg Placebo capsule, taken by mouth, once, with Meal A

Dietary Supplement: PlaceboOther: Meal A

Meal A + Elevase®

EXPERIMENTAL

350 mg Elevase® capsule, taken by mouth, once, with Meal A

Dietary Supplement: Elevase®Other: Meal A

Meal A + DE111®

EXPERIMENTAL

350 mg DE111® capsule, taken by mouth, once, with Meal A

Dietary Supplement: DE111®Other: Meal A

Meal B + Placebo

EXPERIMENTAL

350 mg Placebo capsule, taken by mouth, once, with Meal B

Dietary Supplement: PlaceboOther: Meal B

Interventions

PlaceboDIETARY_SUPPLEMENT

Maltodextrin capsule manufactured to mimic the Elevase® and DE111® capsules

Meal A + PlaceboMeal B + Placebo
Elevase®DIETARY_SUPPLEMENT

1 capsule containing 350 mg of Elevase®

Meal A + Elevase®
DE111®DIETARY_SUPPLEMENT

1 capsule containing Bacillus subtilis DE111

Meal A + DE111®
Meal AOTHER

Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL

Meal A + DE111®Meal A + Elevase®Meal A + Placebo
Meal BOTHER

Refrigerated oatmeal - serving of refrigerated oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL

Meal B + Placebo

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject has given written informed consent
  • Subject has an ileostomy stable for at least 3 months post-operative and shows normal stoma functions
  • Subject is otherwise healthy
  • Subject is available to participate in the study sessions on the proposed dates

You may not qualify if:

  • Subject has coeliac disease or allergy to wheat products and/or any other ingredients in the test meal and standard meals
  • Case of obstruction of the stoma in the past 3 months
  • Body mass index \< 18 kg/m2 or \> 30 kg/m2.
  • Diagnosed mouth, throat or active gastrointestinal pathology (other than ileostomy) that may affect normal ingestion and digestion of food.
  • History of pancreatic disease
  • Subject is immunocompromised (HIV positive, transplant patient, on antirejection medications, on a steroid for \>30 days, or chemotherapy or radiotherapy within the last year)
  • Subject has Type 1 or Type 2 diabetes mellitus.
  • Subject has a history of bariatric surgery.
  • Subject has a history of drug and/or alcohol abuse at the time of enrolment
  • Subject is currently participating in another study, or plans to participate in another study during the study period
  • Women of child-bearing potential who do not use an acceptable method of contraception
  • Pregnant or nursing (lactating) women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Atlantia Food Clinical Trials

Cork, Cork, Ireland

Location

Related Publications (1)

  • Smith F, Pan X, Bellido V, Toole GA, Gates FK, Wickham MS, Shewry PR, Bakalis S, Padfield P, Mills EN. Digestibility of gluten proteins is reduced by baking and enhanced by starch digestion. Mol Nutr Food Res. 2015 Oct;59(10):2034-43. doi: 10.1002/mnfr.201500262. Epub 2015 Aug 21.

    PMID: 26202208BACKGROUND

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Each participant attended a clinic for one day for an acute assessment of the acute effects of treatment. This was done on the same day over 4 consecutive weeks. At each visit the participant received 1 of 4 different treatments
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 22, 2020

First Posted

July 28, 2020

Study Start

October 19, 2020

Primary Completion

April 8, 2021

Study Completion

April 8, 2021

Last Updated

April 10, 2025

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations